- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Tongji University
Headquarters: Shangahai, China
Website: http://www.tongji.edu.cn/eng...
Year Founded: 1907
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Mar 17, 2023
Discovery & Translation
RNA origami to aid delivery; plus sense-and-response ADAR base editing and more
BioCentury's roundup of translational news
BioCentury | Oct 1, 2022
Discovery & Translation
An anti-IgE protein-bacteria combo for food allergy; predicting COVID mutants, Lasker winners and more
BioCentury’s roundup of translational news
BioCentury | Feb 10, 2022
Discovery & Translation
Translational trendspotting: a Distillery dive into neurology
Highlights include a new approach to the amyloid hypothesis, white space strategies for stroke and gene therapies
BioCentury | Jul 30, 2021
Distillery Therapeutics
Peptide inhibitor of LY96 for ischemic and hemorrhagic stroke
DISEASE CATEGORY: Neurology
INDICATION: Stroke A peptide targeting the TLR4 ligand LY96 could treat ischemic and hemorrhagic stroke. The peptide — comprising a domain of the LY96 binding
INDICATION: Stroke A peptide targeting the TLR4 ligand LY96 could treat ischemic and hemorrhagic stroke. The peptide — comprising a domain of the LY96 binding
BioCentury | Jul 30, 2021
Distillery Therapeutics
Delivering the lncRNA NRON to osteoclasts for osteoporosis
DISEASE CATEGORY: Musculoskeletal
INDICATION: Osteoporosis Osteoclast-targeted delivery of the long non-coding RNA (lncRNA) NRON or its NCM2 motif could treat osteoporosis. Plasmid vectors encoding
INDICATION: Osteoporosis Osteoclast-targeted delivery of the long non-coding RNA (lncRNA) NRON or its NCM2 motif could treat osteoporosis. Plasmid vectors encoding
Items per page:
1 - 10 of 27